A Trial of Setanaxib in Patients With Primary Biliary Cholangitis (PBC) and Liver Stiffness
Status:
Not yet recruiting
Trial end date:
2025-09-15
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the effect of setanaxib on biochemical
response at Week 52 in participants with primary biliary cholangitis (PBC) and with elevated
liver stiffness and intolerance or inadequate response to ursodeoxycholic acid (UDCA).